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CASE REPORT Open Access
The clinical and public health problem of relapse
despite primaquine therapy: case review of
repeated relapses of Plasmodium vivax acquired
in Papua New Guinea
R Joan H Ingram1, Chelzie Crenna-Darusallam2, Saraswati Soebianto3, Rintis Noviyanti4 and J Kevin Baird3,4*
Abstract
Background: Primaquine is the only drug available for preventing relapse following a primary attack by Plasmodium
vivax malaria. This drug imposes several important problems: daily dosing over two weeks; toxicity in patients with
glucose-6-phosphate dehydrogenase (G6PD) deficiency; partner blood schizontocides possibly impacting primaquine
safety and efficacy; cytochrome P-450 abnormalities impairing metabolism and therapeutic activity; and some strains of
parasite may be tolerant or resistant to primaquine. There are many possible causes of repeated relapses in a patient
treated with primaquine.
Case description: A 56-year-old Caucasian woman from New Zealand traveled to New Ireland, Papua New Guinea for
two months in 2012. One month after returning home she stopped daily doxycycline prophylaxis against malaria, and
one week later she became acutely ill and hospitalized with a diagnosis of Plasmodium vivax malaria. Over the ensuing
year she suffered four more attacks of vivax malaria at approximately two-months intervals despite consuming
primaquine daily for 14 days after each of those attacks, except the last. Genotype of the patient’s cytochrome P-450
2D6 alleles (*5/*41) corresponded with an intermediate metabolizer phenotype of predicted low activity.
Discussion: Multiple relapses in patients taking primaquine as prescribed present a serious clinical problem, and
understanding the basis of repeated therapeutic failure is a challenging technical problem. This case highlights these
issues in a single traveler, but these problems will also arise as endemic nations approach elimination of malaria
transmission.
Keywords: Plasmodium vivax, Relapse, Primaquine, Resistance, Tolerance, Compliance, Therapeutic failure, CYP2D6
polymorphism
Background
Endemic Plasmodium vivax puts 2.7 billion residents at
risk of infection, and very many visitors [1]. In the USA,
during 1990 to 2010, between 400 and 700 Americans
were diagnosed with vivax malaria each year [2]. In the
UK, between 2002 and 2005, a total of 1,244 cases of P.
vivax malaria were reported [3]. Each primary attack
carries risk of repeated attacks called relapses in the
weeks and months to follow, for up to three years [4].
The probability, number, and timing of relapses vary by
geographic origin of the strain [5]. Three to five relapses
may be considered typical, and up to 20 within two years
have been documented [6].
Despite long being considered relatively benign and
very rarely fatal, recent work demonstrates the potential
for serious morbidity and even mortality with vivax mal-
aria [2,7-11]. Severe anaemia is the most common
threatening syndrome, followed by acute respiratory dis-
tress, kidney failure, severe thrombocytopaenia, coma,
and shock syndromes. Severe and fatal complications in
travellers also occur [7,12]. Preventing repeated attacks
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of relapsing vivax malaria offers the opportunity to avoid
threatening illness and onward transmission.
Primaquine alone has proven safety and efficacy against
the latent parasite in the liver (hypnozoites) responsible
for relapsing vivax malaria. Licensed in 1952, primaquine
has been combined with chloroquine against the asexual
blood stages to achieve radical cure, i.e., elimination of all
forms of the parasite. A wide variety of primaquine regi-
mens have been applied against relapse [13], but today
experts agree that 0.5 mg/kg daily for 14 days should pre-
vent relapse [14].
Primaquine toxicity in glucose-6-phosphate dehydro-
genase (G6PD)-deficient patients imposes several im-
portant obstacles to achieving radical cure. Adherence to
14 days of daily dosing may be unlikely without firm
guidance from the provider and follow up [15]. However,
strict adherence invites risk of serious harm in most
G6PD-deficient patients. So most providers do not offer
primaquine therapy without knowing G6PD status [16].
When providers do offer primaquine, advice to fully ad-
here must include the caution to cease dosing with signs
of haemolysis. A robust point-of-care diagnosis of G6PD
deficiency would mitigate this problem of safe access to
effective therapy against relapse, but not all of them.
Several other problems diminish effectiveness of radical
cure by primaquine. Differential cytochrome P450 2D6
isozyme metabolism of primaquine by dozens of distinct
allelic variants introduces highly complex determinants of
clinical efficacy. Further, the rise of resistance to prima-
quine’s partner in radical cure, chloroquine, requires
adopting other blood schizontocides as therapy, but the
safety and efficacy of primaquine against relapse may vary
when combined with those partner drugs in radical cure
[17]. Each new partner therapy requires new evidence of
primaquine safety and efficacy, and such is relatively diffi-
cult to obtain. Pregnant or lactating women, and infants
may not receive primaquine therapy [18], and these
groups are the most vulnerable to severe and threatening
vivax malaria in endemic communities [19,20].
Sixty years of continuous primaquine use requires
consideration of the potential problem of resistance to it
by hypnozoites. However, as the case described in this
report illustrates, demonstrating either sensitivity or re-
sistance to primaquine is a very complex, multi-tiered
endeavour requiring the ruling out of many possible
confounding factors. Repeated acute attacks of vivax
malaria despite primaquine therapy poses threats to the
health and life of the patient, and puts the care providers
in the difficult position of identifying the cause of thera-
peutic failure in order to address it. These patients also
raise public health issues, especially regarding strategies
for eliminating malaria transmission.
Here, a summary of a case obtained from medical re-
cords and the first author’s clinical review of the patient
is presented to highlight the issue of multiple relapses of
P. vivax despite apparently adequate primaquine therapy.
Case presentation
Travel, attacks and treatment
A 56-year-old woman resident in New Zealand weighing
67 kg arrived at New Ireland, Papua New Guinea in
early September 2012. During that visit she consumed
100 mg doxycycline daily up to the end of travel in late
October 2012 and for one month following return to
New Zealand. She reported being fully compliant with
that chemoprophylaxis. She had previously experienced
an episode of confirmed Plasmodium falciparum after
travel to Africa and wished to avoid another such attack.
A week later, in November 2012, she sought medical at-
tention after developing headache, malaise, and rigors. A
diagnosis of P. vivax was made microscopically (Figure 1).
She spent two days in hospital and was discharged
after responding to therapy with atovaquone/proguanil
(Malarone™, 4 tablets/day × 3 d). She was prescribed an
unknown dose of daily primaquine (Primacin™, BNM®,
Australia) for this first attack after her G6PD test was
normal.
Two months later, in January 2013 she suffered a sec-
ond attack, again confirmed with a microscopic diagno-
sis and with admission to hospital. She was treated
with artemether/lumefantrine (Riamet™, 4 tablets twice
daily for 3 days) and 30 mg primaquine base daily for
14 days.
Two months later, in March 2013, she suffered a third
confirmed attack of P. vivax malaria and was hospital-
ized for several days. She received the same therapy as
that prescribed after the second attack. The patient de-
scribed being fully compliant to daily primaquine ther-
apy with prior treatments. The importance of doing so
was again emphasized to the patient.
A fourth attack occurred two months later in May
2013. She was admitted to hospital with a peripheral
parasitaemia of asexual P. vivax trophozoites infecting
3-4% of her red blood cells. She was treated with the
same regimen of therapy as after the second and third
attacks, but with 45 mg primaquine daily for 14 days, ra-
ther than 30 mg. She spent one day in hospital.
The fifth attack again occurred two months later, in
July 2013. She was not admitted to hospital and con-
sumed artemether/lumefantrine as before. Primaquine
therapy was judged unlikely to provide any benefit and
was not prescribed.
In August 2013 the patient travelled to the Solomon
Islands and remained for two months, all the while con-
suming a commercial dietary supplement containing
Artemisia annua herbal extract (equivalent of 17 mg ar-
temisinin daily) that had been recommended to her by a
colleague for malaria prevention. She remained healthy
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while abroad. Five months after returning to New Zealand,
she again suffered an attack of vivax malaria (March 2014).
This was treated initially and partially with chloroquine
(two doses) with a switch to atovaquone/proguanil, and
primaquine was again not prescribed for the same reasons
as in July 2013.
The patient travelled to Vanuatu for two weeks in
April and May 2014, taking 100 mg doxycycline daily
while there, and continues that regimen up to December
2014 with intervening travel to the Solomon Islands. As
of December 2014 she has not suffered any attacks of
malaria since March 2014, but has on three occasions
developed severe headache, weakness and chills which
have settled within 24 hours without medical attention.
Although these six episodes of vivax malaria were not
complicated, each caused marked symptoms and most
led to admission to hospital. These events were debilitat-
ing and disruptive of the patient’s routines, and she
firmly declared that she took the four courses of prima-
quine precisely as directed.
Plasmodium diagnostics
Giemsa-stained thin blood films were taken at each pres-
entation with acute illness. Demonstration of amoeboid
trophozoites within enlarged infected red blood cells
provided the diagnosis of vivax malaria (Figure 1) at the
laboratory. Expert malaria microscopists at the Eijkman-
Oxford Clinical Research Unit in Jakarta, Indonesia af-
firmed that diagnosis. At the molecular diagnostic refer-
ral laboratory also in Jakarta (Eijkman Institute for
Molecular Biology), a vial of extracted DNA from blood
taken at the final attack of malaria was analyzed by
nested PCR of ssrRNA using standardized methodology
employing genus and species-specific primers (for Plas-
modium malariae, Plasmodium ovale, P. falciparum,
and P. vivax) [21]. These were strongly positive for P.
vivax and negative for the other species.
CYP2D6 genotyping
Isolated DNA was collected from the patient and extracted
using Puregene™ (Gentra®) and its concentration measured
at 635 ng/μL (NanoDrop2000™, Thermoscientific®) and
1.58 DNA purity (A260/A280). CYP2D6 genotyping was
performed using xTAG™ CYP2D6 kit v3 (Luminex® Cor-
poration, USA). Allelic variation categories assayed by this
kit included DNA sequences encoding normal function
(*1, *2, and *35), reduced function (*9, *10, *17, *29, and
*41), and non-functional (*3, *4, *5 –for whole-gene dele-
tion, *6, *7, *8, *11, and *15), including DUP for duplica-
tion. The manufacturer’s instructions were followed for
genotyping by this kit. Amplification and incubation was
performed using 9700 thermal cycler (PE Applied Biosys-
tems®). The Luminex® 200 xMAP™ instrument was used to
read the fluorescence absorbance from a specific probe
that hybridized with the beads. The data were then ana-
lysed automatically using the xTAG Data Analysis Soft-
ware™ to record the CYP2D6 allelic variant.
A CYP2D6 gene deletion (*5) and polymorphisms at
1661G > C, 2850C > T, 2988G > A, and 4180G > C (*41)
were detected. The genotype of the patient was classified
as a *5/*41 allelic variant. According to the prediction of
enzymatic activity, the *5 and *41 allelic variants are cat-
egorized as null and dysfunctional, respectively [22,23].
The combination of those allelic variants infers an inter-
mediate metabolizer phenotype (Figure 2). Nonetheless,
*41 allele is frequently associated with relatively very low
enzymatic activity scores when expressed with the null
*5, i.e., 0.5 on a scale of 0 to 3, where 3 is the ultra-
metabolizer, and 1.5 to 2.0 represent wild type *1/*1
scores [24]. Absent direct characterization of CYP2D6
metabolizer phenotype – as may be done with a dextro-
methorphan challenge and pharmacokinetic analysis
[25] – it can only be considered it likely that the CYP2D6
genotype in this patient resulted in levels of metabolized
primaquine inadequate to the task of killing hypnozoites
Figure 1 Photomicrograph of an oil-immersion microscopic examination of a Giemsa-stained thin blood smear taken from the patient
illustrating amoeboid trophozoites within enlarged and mutable infected red blood cells consistent with a diagnosis of infection by
Plasmodium vivax.
Ingram et al. Malaria Journal 2014, 13:488 Page 3 of 7
http://www.malariajournal.com/content/13/1/488
of P. vivax. Likewise, one research subject experimentally
challenged with P. vivax and relapsing despite directly ob-
served high-dose primaquine therapy had *4/*41 genotype
of CYP2D6 [26], where *4 has no functional enzyme activ-
ity (like the *5 deletion) [23].
Interpretation
This patient suffered an attack of Plasmodium vivax
post-travel, followed by four relapses, each at two-month
intervals, and a fifth attack more than six months after
the prior attack and intervening travel to another mal-
aria endemic area. She consumed full courses of prima-
quine after the first, second, third, and fourth attacks,
including a round of 45 mg/day for 14 days. None of
these prevented her from relapsing at intervals typical of
P. vivax from that region [5]. The challenge for her care
providers, and malariologists weighing strategies for
elimination of this parasite, is to understand what failed
in this case and what may be done to avoid such poor
therapeutic outcomes in the future.
The Plasmodium vivax strain called Chesson came
from an American soldier infected in 1944 during the
New Guinea campaign of the Pacific War [27]. This
strain and most from the Pacific region relapse quickly
(usually within a month of onset of the primary attack)
and at approximately two-month intervals [28]. Chesson
P. vivax also tolerated 14-day courses of primaquine at
0.25 mg/kg daily, necessitating 0.5 mg/kg daily for good
efficacy [29]. The parasite infecting the patient described
here also came from the New Guinea region and appears
Chesson-like in its relapsing behaviour, and proved un-
responsive to even 0.75 mg/kg daily primaquine therapy
for 14 days. Understanding why primaquine failed in this
patient requires considering many possible explanations,
including failure to take therapy as directed, inappropriate
partner blood schizontocide, counterfeit or substandard
primaquine, re-infection, or polymorphisms in the sole
human cytochrome P-450 isozyme (2D6, or CYP2D6) [30]
known to metabolize primaquine [31], an essential step in
killing hypnozoites [32].
Bennett and colleagues [26] challenged 25 human sub-
jects with P. vivax sporozoites, and all suffered a primary
attack and were treated with directly observed standard
chloroquine and primaquine (0.5 mg/kg/d × 14 d) radical
cure. Two subjects nonetheless relapsed. The CYP2D6
genotypes of those two subjects were classified as associ-
ated with intermediate or poor metabolizers, respectively.
The intermediate metabolizer relapsed twice, and the
poor metabolizer relapsed three times. Among the 23
subjects who did not relapse, only two were classified as
intermediate metabolizers, and the remaining 21 subjects
were extensive metabolizers. Higher levels of un-
metabolized primaquine in plasma among the defective
metabolizers suggested far lower rates of conversion to
Figure 2 Phenotype prediction from CYP2D6 allelic variants detected by the xTAG™ CYP2D6 Kit v3 (Luminex® Corp., USA). Green
corresponds to extensive metabolizer (EM), yellow to intermediate metabolizer (IM), and red to poor metabolizer phenotypes. Our patient’s
genotype placement at *5/*41 is shown as blue in an intermediate metabolizer phenotype.
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active metabolites. These findings tended to rule out para-
site resistance to primaquine as the explanation of the
therapeutic failures. Taken with the facts of directly ob-
served therapy and no possible re-infection, those studies
pointed to CYP2D6 polymorphisms as being important
determinants of efficacy against relapse.
Likewise, a specific CYP2D6 genotype in this patient
(*5/*41) seems to account for the poor outcomes of her
repeated rounds of primaquine therapy. The parasite in-
fecting the patient relapsed at its naturally short intervals
(two months), seemingly unaffected by the primaquine be-
ing consumed. Primaquine exerts a cumulative dose effect
on hypnozoites called the total dose effect, where the total
dose determines efficacy rather than the schedule of deliv-
ery [33]. In other words, the same total dose may be deliv-
ered as single dose, as 7 or 14 daily doses, or as weekly
doses for eight weeks and achieve the same good efficacy
[34]. Whereas a total dose of 420 mg is considered effica-
cious against even the primaquine-tolerant Chesson strain
of P. vivax, this patient received a total dose of 1,890 mg
over an eight-month period, relapsing repeatedly in that
interval. Even this very large cumulative total dose ap-
peared inadequate against relapse.
Another possible explanation for therapeutic failure is
the role of unproven partner blood schizontocides given
to this patient. Her care providers prescribed atovaquone-
proguanil and, later, artemether-lumefantrine. Resistance
to chloroquine by P. vivax in the Asia-Pacific region is
widely known [35]. The safety and efficacy of primaquine
against relapse depends on the partner blood schizonto-
cide [17]. No clinical trials have proven primaquine safe
and effective when used with either of those blood schi-
zontocidal therapies as partner in radical cure. Drug-drug
interactions between those therapies somehow disabling
therapeutic efficacy against relapse cannot be ruled out in
this patient. Poor adherence or faulty primaquine cannot
be ruled out, but are considered very unlikely. The pa-
tient’s CYP2D6 polymorphism was considered the most
likely basis of her experiences with P. vivax.
Implications
Primaquine has been the sole therapy against relapse of
vivax malaria since 1952. The parasite has certainly been
exposed to sub-therapeutic levels over that period [13].
Acquired resistance to primaquine must be regarded as
a possibility, even though hypnozoite resistance to prima-
quine has yet to be demonstrated in animal models,
patients, or study subjects. This may be a product of re-
sistance being absent, or of the difficulty of ruling out all
other possible causes of therapeutic failure.
No standardized in vivo protocol has been developed,
optimized or validated for the diagnosis of resistance to
primaquine in a patient. Re-infection would seriously
confound the assessment of primaquine sensitivity, and
no molecular diagnostics today differentiate relapse from
reinfection. Randomized clinical trials can measure the
force of infection of blood via hypnozoites versus sporo-
zoites in populations [36], but such trials are extremely
laborious and expensive, and not practical for routine
surveillance. All of these difficulties explain why we can-
not now conduct surveillance for primaquine resistance/
efficacy in endemic areas. Thus, primaquine efficacy in
most settings cannot be known. An analysis of 87 prima-
quine therapeutic trials since 1950 by John et al. [37] il-
lustrates an attempt at doing so despite the limitations
and confounders involved.
Only under relatively rare circumstances – as in experi-
mental challenge or in mobile populations from non-
endemic areas being briefly heavily exposed and then
repatriated – can the efficacy of primaquine be measured
with little or no ambiguity. In one such instance, the effi-
cacy of primaquine against hypnozoites acquired in
Indonesian New Guinea was a remarkable 98% at 0.5 mg/
kg/day X 14d following dihydroartemisinin-piperaquine as
partner blood schizontocide [38]. That one study offers
hope of good efficacy elsewhere, but does not substitute
for a responsibly thorough and effective means of surveil-
lance for resistance to primaquine.
Travellers returning home and suffering vivax malaria
may be the sole means now available to reliably estimate
the efficacy of primaquine against relapse in any given
area. The technical difficulty of interpreting outcomes in
this patient in New Zealand illustrates the complexity in
understanding the broader determinants of therapeutic
efficacy against relapse. The extraordinary diversity and
complexity of CYP2D6 polymorphisms will require a
great deal more attention in the context of malaria con-
trol and elimination. The current case illustrates the
value of CYP2D6 assessment in patients needing prima-
quine therapy.
Conclusions
The findings in this case review are compatible with
therapeutic failure of primaquine as a consequence of a
polymorphism of CYP2D6 (*5/*41) impairing metabol-
ism to an active form. Unproven combinations of ACT
therapies with primaquine for radical cure exacerbating
therapeutic inadequacy may not be ruled out, along with
other factors like adherence and sub-standard drug. De-
fining the determinants of primaquine therapeutic fail-
ure against relapse clarifies strategy aimed at achieving
maximal effectiveness of primaquine against the hypno-
zoite reservoir of P. vivax. Elimination of vivax malaria
may hinge upon success at doing so.
Consent
Written informed consent was obtained from the patient
for publication of this case study and accompanying
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